277.2 𩺠åèç
277.2.1 é«é »èé»
277.2.1.1 Drug Mechanism + Indications
- ACEi/ARB: â Ang II â vasodilate; DM + CKD + HFrEF + post-MI
- CCB-DHP: vasodilate; elderly, African Americans, angina, pregnancy
- CCB-non-DHP: â HR + contractility; AF rate control
- Thiazide: chlorthalidone preferred; HFpEF, African Americans
- β-blocker: post-MI, HFrEF, angina, AF, migraine, pregnancy (labetalol)
- MRA: resistant HTN, HFrEF; spironolactone first
277.2.1.2 Compelling Indications Algorithm
| Comorbidity | First-line |
|---|---|
| HFrEF | ARNI/ACEi/ARB + β-blocker + MRA + SGLT2i |
| Post-MI | β-blocker + ACEi/ARB + MRA |
| CKD + proteinuria | ACEi/ARB |
| DM | ACEi/ARB |
| AF | β-blocker or non-DHP CCB |
| Angina | β-blocker, CCB |
| BPH | α-blocker (add-on) |
| Migraine | β-blocker |
| Pregnancy | Methyldopa, labetalol, nifedipine |
277.2.1.3 Key Trials
- SPRINT 2015: < 120 vs < 140 â intensive better
- STEP 2021: Chinese elderly, same benefit
- PATHWAY-2 2015: spironolactone best 4th drug
- ALLHAT 2002: chlorthalidone > amlodipine > lisinopril (overall similar)
- ASCOT-BPLA 2005: amlodipine + perindopril > atenolol + thiazide
- HOPE 1999: ramipril â MACE
- SSaSS 2021: salt substitute â stroke + death
- SYMPLICITY HTN-3 / SPYRAL-HTN-OFF / RADIANCE-HTN: renal denervation
277.2.2 ææ··æ·æ¯èŒ
| Drug Class | Black Patients | DM | CKD | HF | Pregnancy |
|---|---|---|---|---|---|
| ACEi/ARB | Less effective alone | First-line | First-line | First-line | AVOID |
| CCB-DHP | Effective | Add-on | Add-on | OK | First-line |
| Thiazide | First-line | Add-on | Avoid eGFR<30 | OK (HFpEF) | OK |
| β-blocker | Less effective alone | OK | OK | First-line (rEF) | Labetalol OK |
| MRA | OK | OK (watch K) | OK | First-line (rEF) | AVOID |